TransMedics Group (NASDAQ:TMDX) Stock Price Up 4.7%

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares were up 4.7% during mid-day trading on Wednesday . The company traded as high as $76.02 and last traded at $76.00. Approximately 59,467 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 623,417 shares. The stock had previously closed at $72.62.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of recent research reports. JPMorgan Chase & Co. increased their target price on TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. Morgan Stanley increased their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 28th. Oppenheimer increased their target price on TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 27th. Finally, Piper Sandler began coverage on TransMedics Group in a research report on Thursday, March 28th. They set an "overweight" rating and a $95.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $102.00.

TransMedics Group Price Performance

The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The company has a market capitalization of $2.46 billion, a PE ratio of -97.86 and a beta of 1.99. The firm has a 50-day moving average of $82.44 and a 200 day moving average of $70.53.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. The business had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business's revenue for the quarter was up 158.6% on a year-over-year basis. During the same period last year, the firm posted ($0.21) earnings per share. As a group, research analysts anticipate that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the firm's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the transaction, the chief financial officer now directly owns 23,299 shares of the company's stock, valued at $1,724,358.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Tamer I. Khayal sold 10,000 shares of the firm's stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total value of $804,100.00. Following the transaction, the insider now owns 14,375 shares of the company's stock, valued at $1,155,893.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Gordon sold 15,000 shares of the firm's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the completion of the transaction, the chief financial officer now directly owns 23,299 shares in the company, valued at approximately $1,724,358.99. The disclosure for this sale can be found here. Over the last three months, insiders have sold 92,949 shares of company stock valued at $7,664,819. Insiders own 6.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Harbour Capital Advisors LLC raised its stake in shares of TransMedics Group by 1.7% in the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company's stock worth $627,000 after buying an additional 140 shares during the period. First Horizon Advisors Inc. raised its stake in shares of TransMedics Group by 45.1% in the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after buying an additional 169 shares during the period. Belpointe Asset Management LLC raised its stake in shares of TransMedics Group by 51.6% in the first quarter. Belpointe Asset Management LLC now owns 558 shares of the company's stock worth $42,000 after buying an additional 190 shares during the period. RiverPark Advisors LLC raised its stake in TransMedics Group by 19.5% during the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company's stock valued at $104,000 after purchasing an additional 215 shares during the period. Finally, Ameritas Investment Partners Inc. raised its stake in TransMedics Group by 9.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,620 shares of the company's stock valued at $220,000 after purchasing an additional 228 shares during the period. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.